Skip to main content
. 2019 Dec 18;14(5):644–651. doi: 10.5009/gnl19272

Table 5.

Awareness and Treatment of HCV Infection

Variable Anti-HCV-positive persons HCV RNA-positive persons*


Yes p-value Yes p-value
Diagnosed as hepatitis C by a doctor
All responders 15.2 (35/230) 30.5 (18/59)
Age group, yr 0.310 0.768
<40 3.8 (1/26) 0.0 (0/2)
40–49 24.0 (6/25) 50.0 (2/4)
50–59 13.0 (7/54) 25.0 (3/11)
60–69 18.5 (10/54) 33.3 (5/15)
≥70 15.5 (11/71) 30.8 (8/26)
Sex 0.179 0.084
Male 18.8 (19/101) 43.5 (10/23)
Female 12.4 (16/129) 22.2 (8/36)
Area of residence 0.651 0.755
Rural 16.9 (11/65) 33.3 (6/18)
Urban 14.5 (24/165) 29.3 (12/41)
Education 0.102 0.005
<High school 12.2 (17/139) 18.9 (7/37)
≥High school 20.2 (18/89) 55.5 (11/20)
Family income 0.209 0.575
Low to mid-low 17.8 (24/135) 32.6 (14/43)
Mid-high to high 11.7 (11/94) 25.0 (4/16)
Prevalence of anti-HCV 0.289 0.354
Lower prevalent area 13.8 (24/174) 26.8 (11/41)
Higher prevalent area 19.6 (11/56) 38.9 (7/18)
ALT, U/L 0.082 0.592
<40 13.4 (26/194) 28.2 (11/39)
≥40 25.0 (9/36) 35.0 (7/20)
Treatment for HCV infection 5.2 (12/230) 13.5 (8/59)

Data are presented as percent (number/number).

HCV, hepatitis C virus; ALT, alanine aminotransferase.

*HCV RNA was measured between 2012 and 2015.